Article quick-view

Central administration of TRV027 improves baroreflex sensitivity and vascular reactivity in spontaneously hypertensive rats.


TRV027 is a biased agonist for the Angiotensin (Ang)-II type 1 receptor (ATR), able to recruit ß-arrestin 2 independently of G-proteins activation. ß-arrestin activation in the central nervous system (CNS) was suggested to oppose the effects of Ang-II. This study evaluates the effect of central infusion of TRV027 on arterial pressure (AP), autonomic function, baroreflex sensitivity and peripheral vascular reactivity. Spontaneously hypertensive (SH) and Wistar Kyoto (WKY) rats were treated with TRV027 for 14 days (20 ng/hour) delivered to the lateral ventricle via osmotic minipumps. Mechanistic studies were performed in HEK293T cells co-transfected with ATR and angiotensin converting enzyme type 2 (ACE2) treated with TRV027 (100 nM) or Ang-II (100 nM). TRV027 infusion in SHR reduced AP (~20 mmHg, <0.05), sympathetic vasomotor activity (ΔMAP = -47.2 ±2.8 -64 ±5.1 mmHg, < 0.05) and low-frequency (LF) oscillations of AP (1.7 ±0.2 5.8 ±0.4 mmHg, <0.05) compared to the SHR control group. TRV027 also increased vagal tone, improved baroreflex sensitivity, reduced the reactivity of mesenteric arteries to Ang-II and increased vascular sensitivity to phenylephrine, acetylcholine and sodium nitroprusside. , TRV027 prevented the Ang-II-induced up-regulation of ADAM17 and in contrast to Ang-II, had no effects on ACE2 activity and expression levels. Furthermore, TRV027 induced lesser interactions between ATR and ACE2 compared to Ang-II. Together, these data suggest that due to its biased activity for the ß-arrestin pathway, TRV027 has beneficial effects within the CNS on hypertension, autonomic and vascular function, possibly through preserving ACE2 compensatory activity in neurons. ©2018 The Author(s).